Albireo Announces Positive Clinical Data on A3309 in Patients with Chronic Idiopathic Constipation

GOTHENBURG, Sweden, November 18 - Albireo today announced the completion of a phase 1b study showing a
favourable tolerability and safety profile of A3309 in patients with chronic
idiopathic constipation. In addition, the data revealed appropriate efficacy
signals in this patient population. A3309 is a first in class compound
developed for the treatment of chronic idiopathic constipation and
constipation-predominant Irritable Bowel Syndrome (IBS-C). Based on these
results, Albireo expects to recruit 180 patients with chronic idiopathic
constipation in a US phase 2b study (www.clinicaltrials.gov) under an
IND recently placed into effect by the FDA.

Notes for Editors:

About CIC

Constipation is one of the most common gastrointestinal complaints.
Chronic idiopathic constipation is a more severe and disabling disease, which
is not effectively managed by current treatment options. More than 4 million
Americans have chronic constipation resulting in 9 million physician visits
annually and in addition lead to more than 92,000 hospitalizations annually.
In a survey study of 557 individuals with chronic constipation, 47% of
respondents indicated a lack of satisfaction with treatment (82% citing lack
of treatment efficacy as the reason for dissatisfaction).

About A3309

A3309 is a therapeutic alternative with a novel mechanism of action
developed for the treatment of chronic idiopathic constipation and
constipation-predominant Irritable Bowel Syndrome (IBS-C). A3309 modulates
the re-uptake of bile acids by inhibiting the ileal bile acid transporter.
This will result in an increased concentration of bile acids in the colon
which, in turn, increase fluid secretion and colonic motility. These
physiological responses should provide benefits to patients with chronic
constipation and IBS-C without any effects on other parts of the
gastrointestinal tract.

About Albireo

Albireo is an independent Swedish biotechnology company focused on the
development of novel therapeutic alternatives to fulfill medical needs in the
gastrointestinal area. Albireo was spun-out of AstraZeneca in February 2008
and is financed by a syndicate of growth capital firms, including Nomura
Phase4 Ventures, TPG growth, TVM Capital and Scottish Widows Investment
Partnership. The company has raised $40m in its Series A financing round
(www.albireopharma.com).

Jan Mattsson, VP Operations, Albireo AB, +46-31-741-14-84 (direct), +46-768-08-35-04 (mobile)